Profile: Denali Therapeutics Inc (DNLI.OQ)
24 May 2019
Denali Therapeutics Inc., incorporated on October 14, 2013 is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately three specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration.
The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, ATV:TREM2, and ATV:BACE1/Tau.
Denali Therapeutics Inc
161 Oyster Point Blvd
SOUTH SAN FRANCISCO CA 94080-1910